𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Detection rates of high-grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer

✍ Scribed by Theodorus H. van der Kwast; Stefano Ciatto; Paula M. Martikainen; Robert Hoedemaeker; Marita Laurila; Carl-Gustaph Pihl; Jonas Hugosson; Ingrid Neetens; Vera Nelen; Simonetta Di Lollo; Monique J. Roobol; Liisa Määtänen; Carlos Santonja; Sue Moss; Fritz H. Schröder

Publisher
John Wiley and Sons
Year
2006
Tongue
French
Weight
137 KB
Volume
118
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Screening for prostate cancer using prostate‐specific antigen (PSA) tests has led to a stage and grade shift as compared to the pre‐PSA era. Effectiveness of screening for prostate cancer should be manifested by a reduction in detection rate of aggressive cancers during subsequent screening. In 6 centers of the European Randomized Screening study for Prostate Cancer, a total of 58,710 men were tested for prostate cancer. Screening centers differed with regard to age‐range, screening interval and biopsy indications. During the 2nd visit, the proportion of Gleason score 6 cancers increased from 62.5 to 75%, mainly at the expense of Gleason score 7 cancers. High‐grade (Gleason score 8–10) cancer detection rates varied per screening center during the 1st visit from 5.1 to 41.1, and during the 2nd visit from 6.4 to 29.3/10,000 men. The overall detection rate of high‐grade cancers showed a reduction during the 2nd visit from 26 to 12/10,000 men, an effect mainly attributable to the screening center with the highest cancer detection rate (i.e. 507/10,000 men). Variations in detection rates among screening centers related among others to biopsy compliance and age range. © 2005 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

The European randomized study of screeni
The European randomized study of screening for prostate cancer : An update
✍ Bo Standaert; Louis Denis 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB 👁 2 views

## Background: A consensus meeting on screening and global strategy for prostate carcinoma, held in antwerp in 1994, determined the willingness among european cancer prevention centers to pursue vigorously the collaborative formation of a multinational randomized screening trial. this trial was to

PSA doubling time predicts the outcome a
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section
✍ Khatami Ali; Aus Gunnar; Damber Jan-Erik; Lilja Hans; Lodding Pär; Hugosson Jona 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 127 KB 👁 2 views

## Abstract This study reports the outcome of active surveillance in men with PSA screening‐detected prostate cancer (PC), and PSA doubling time (PSADT) was evaluated as a predictor of selecting patients to active treatment or surveillance. On December 31, 1994, 10,000 men were randomized to bienni

Changing role of 3 screening modalities
Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam)
✍ P.M.M. Beemsterboer; R. Kranse; H.J. de Koning; J.D.F. Habbema; F.H. Schröder 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 88 KB 👁 2 views

A randomized screening trial was started in Europe to show the effect of early detection and treatment of prostate cancer on mortality (European Study on Screening of Prostate Cancer). In one centre (Rotterdam), the screening protocol initially consisted of 3 screening tests for all men: prostate-sp

Predictors for biopsy outcome in the Eur
Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam Region)
✍ Kranse, Ries; Beemsterboer, Petra; Rietbergen, John; Habbema, Dik; Hugosson, Jon 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 2 views

In the European Randomized Study of Screening for Prostate Cancer (ER-SPC, Rotterdam region), men aged 55-74 years are screened for prostate cancer by prostatespecific antigen (PSA) sampling, digital rectal examination (DRE), and transrectal ultrasound investigation (TRUS). All men with a PSA Ն4 ng/

Effective PSA contamination in the Rotte
Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer
✍ Suzie J. Otto; Ingrid W. van der Cruijsen; Michael K. Liem; Ida J. Korfage; Jan 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 93 KB 👁 2 views

## Abstract The extent of effective prostate‐specific antigen (PSA) contamination in the Rotterdam section of the ongoing European Randomized Study of Screening for Prostate Cancer (ERSPC) trial was evaluated and defined as when opportunistic PSA testing of ≥ 3.0 ng/ml was followed by biopsy, simil

Impact of recent screening on predicting
Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen : Data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
✍ Andrew J. Vickers; Angel M. Cronin; Gunnar Aus; Carl-Gustav Pihl; Charlotte Beck 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 266 KB 👁 2 views

## Abstract ## BACKGROUND: Risk models to predict prostate cancer on biopsy, whether they include only prostate‐specific antigen (PSA) or other markers, are intended for use in all men of screening age. However, the association between PSA and cancer probably depends on a man's recent screening hi